A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose.
A Phase II/III, Randomized, Double-blinded Study to Evaluate the Efficacy, Safety and Immunogenicity of a Booster Dose of PIKA Recombinant SARS-CoV-2 Vaccine in Adults Who Received 2 or More Doses of Inactivated Covid-19 Vaccine.
Sponsor: Yisheng Biopharma (Singapore) Pte. Ltd.
Listed as NCT05463419, this PHASE2/PHASE3 trial focuses on Covid-19 Vaccine and remains completed. Sponsored by Yisheng Biopharma (Singapore) Pte. Ltd., it has been updated 10 times since 2022, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Status: Active Not Recruiting → Completed
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Mar 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2_PHASE3
▶ Show 5 earlier versions
-
Dec 2023 — Mar 2024 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Nov 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Mar 2023 — Nov 2023 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2023 — Mar 2023 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2022 — Jan 2023 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Yisheng Biopharma (Singapore) Pte. Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .